156 related articles for article (PubMed ID: 36652274)
21. What Should We Know about Drug Levels and Therapeutic Drug Monitoring during Pregnancy and Breastfeeding in Inflammatory Bowel Disease under Biologic Therapy?
Barrau M; Roblin X; Andromaque L; Rozieres A; Faure M; Paul S; Nancey S
J Clin Med; 2023 Dec; 12(23):. PubMed ID: 38068547
[TBL] [Abstract][Full Text] [Related]
22. Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation.
Duricova D; Dvorakova E; Hradsky O; Mitrova K; Durilova M; Kozeluhova J; Kohout P; Zarubova K; Bronsky J; Hradska N; Bronska E; Adamcova M; Machkova N; Hruba V; Bortlik M; Lukas M; Malickova K; Lukas M
Inflamm Bowel Dis; 2019 Mar; 25(4):789-796. PubMed ID: 30239799
[TBL] [Abstract][Full Text] [Related]
23. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series.
Lund T; Thomsen SF
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28071837
[TBL] [Abstract][Full Text] [Related]
24. A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy.
Picardo S; Seow CH
Drugs; 2019 Jul; 79(10):1053-1063. PubMed ID: 31183768
[TBL] [Abstract][Full Text] [Related]
25. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
[TBL] [Abstract][Full Text] [Related]
26. Suboptimal Vaccination Administration in Mothers With Inflammatory Bowel Disease and Their Biologic-Exposed Infants.
Chiarella-Redfern H; Lee S; Jubran B; Sharifi N; Panaccione R; Constantinescu C; Benchimol EI; Seow CH
Inflamm Bowel Dis; 2022 Jan; 28(1):79-86. PubMed ID: 33609034
[TBL] [Abstract][Full Text] [Related]
27. Physiologically-Based Pharmacokinetic Modeling of Anti-Tumor Necrosis Factor Agents for Inflammatory Bowel Disease Patients to Predict the Withdrawal Time in Pregnancy and Vaccine Time in Infants.
Chen J; Lin R; Guo G; Wu W; Ke M; Ke C; Huang P; Lin C
Clin Pharmacol Ther; 2023 Dec; 114(6):1254-1263. PubMed ID: 37620249
[TBL] [Abstract][Full Text] [Related]
28. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
29. Management of biologics in pregnant, lactating patients with inflammatory bowel disease and the impact on neonatal vaccination: A systematic review of clinical practice guidelines and consensus statements.
Ding N; Zhao L; Zhu L; Sun W; Li D; Li J; Zhang J; Zhang S
J Clin Pharm Ther; 2022 Dec; 47(12):1952-1965. PubMed ID: 36452989
[TBL] [Abstract][Full Text] [Related]
30. Compliance of mothers following recommendations to breastfeed or withhold breast milk during rotavirus vaccination in North India: a randomized clinical trial.
Rongsen-Chandola T; Winje BA; Goyal N; Rathore SS; Mahesh M; Ranjan R; Arya A; Rafiqi FA; Bhandari N; Strand TA
Trials; 2014 Jun; 15():256. PubMed ID: 24976452
[TBL] [Abstract][Full Text] [Related]
31. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Liu Z; Le K; Zhou X; Alexander JL; Lin S; Bewshea C; Chanchlani N; Nice R; McDonald TJ; Lamb CA; Sebastian S; Kok K; Lees CW; Hart AL; Pollok RC; Boyton RJ; Altmann DM; Pollock KM; Goodhand JR; Kennedy NA; Ahmad T; Powell N;
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):145-156. PubMed ID: 36481043
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.
Holko P; Kawalec P; Pilc A
Pharmacoeconomics; 2018 Jul; 36(7):853-865. PubMed ID: 29667146
[TBL] [Abstract][Full Text] [Related]
33. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
[TBL] [Abstract][Full Text] [Related]
34. Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial.
Tameris M; Mearns H; Penn-Nicholson A; Gregg Y; Bilek N; Mabwe S; Geldenhuys H; Shenje J; Luabeya AKK; Murillo I; Doce J; Aguilo N; Marinova D; Puentes E; Rodríguez E; Gonzalo-Asensio J; Fritzell B; Thole J; Martin C; Scriba TJ; Hatherill M;
Lancet Respir Med; 2019 Sep; 7(9):757-770. PubMed ID: 31416768
[TBL] [Abstract][Full Text] [Related]
35. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease.
Gisbert JP; Chaparro M
Am J Gastroenterol; 2013 Sep; 108(9):1426-38. PubMed ID: 23752881
[TBL] [Abstract][Full Text] [Related]
36. Effect of withholding breastfeeding on the immune response to a live oral rotavirus vaccine in North Indian infants.
Rongsen-Chandola T; Strand TA; Goyal N; Flem E; Rathore SS; Arya A; Winje BA; Lazarus R; Shanmugasundaram E; Babji S; Sommerfelt H; Vainio K; Kang G; Bhandari N
Vaccine; 2014 Aug; 32 Suppl 1():A134-9. PubMed ID: 25091668
[TBL] [Abstract][Full Text] [Related]
37. Vedolizumab and Ustekinumab Levels in Pregnant Women With Inflammatory Bowel Disease and Infants Exposed In Utero.
Prentice R; Flanagan E; Wright EK; Gibson PR; Rosella S; Rosella O; Begun J; An YK; Lawrance IC; Kamm MA; Sparrow M; Goldberg R; Prideaux L; Vogrin S; Kiburg KV; Ross AL; Burns M; Bell SJ
Clin Gastroenterol Hepatol; 2024 Mar; ():. PubMed ID: 38492905
[TBL] [Abstract][Full Text] [Related]
38. The inexorable increase of biologic exposure in paediatric inflammatory bowel disease: a Scottish, population-based, longitudinal study.
Burgess CJ; Jackson R; Chalmers I; Russell RK; Hansen R; Scott G; Henderson P; Wilson DC
Aliment Pharmacol Ther; 2022 Nov; 56(10):1453-1459. PubMed ID: 36196524
[TBL] [Abstract][Full Text] [Related]
39. Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants.
Bove R; Hellwig K; Pasquarelli N; Borriello F; Dobson R; Oreja-Guevara C; Lin CJ; Zecevic D; Craveiro L; McElrath T; Vukusic S
Mult Scler Relat Disord; 2022 Aug; 64():103963. PubMed ID: 35753176
[TBL] [Abstract][Full Text] [Related]
40. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
Ko Y; Paramsothy S; Yau Y; Leong RW
Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
